

**Marker Therapeutics, Inc.**  
**3200 Southwest Freeway, Suite 2240**  
**Houston, TX 77027**

June 21, 2019

VIA EDGAR

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attn: Tonya Aldave

**RE:   Marker Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**File No. 333-232122**

**Acceleration Request**

**Requested Date:   June 25, 2019**  
**Requested Time:   4:00 P.M. Eastern Time**

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “**Registrant**”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “**Registration Statement**”) to become effective on June 25, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Madison A. Jones at (202) 728-7087.

Very truly yours,

**Marker Therapeutics, Inc.**

/s/ Peter Hoang.  
Peter Hoang  
President and Chief Executive Officer

cc:    Anthony Kim, Chief Financial Officer  
      Ken Moseley, J.D., Senior Vice President and General Counsel  
      Divakar Gupta, Cooley LLP  
      Darren DeStefano, Cooley LLP  
      Madison A. Jones, Cooley LLP

---